News:
Inovio’s Ebola Vaccine Provides 100% Protection And Elicits Long-Lasting Immune Responses in Preclinical Studies
Inovio Successfully Develops First DNA-Encoded Monoclonal Antibody (dMAb™) Checkpoint Inhibitor and Demonstrates Tumor Shrinkage in Preclinical Studies
Major Cancer Journal Highlights Data From An Inovio-Sponsored Trial In Which A Patient Achieved Full Remission After Dosing With DNA Immunotherapy and Checkpoint Inhibitor
Inovio is where
IMMUNO-INGENUITY is making the difference for patients with cancer and infectious diseases.
“At Inovio, the revolutionary power of our technology is superseded only by the dedication, passion, and expertise of the team we have brought together to bring our technology to life for patients in need.”
J. Joseph Kim, Ph.D.
President and CEO
Investor information
Review Inovio’s investor presentation highlighting our science, progress, and key upcoming milestones.
Inovio is focusing on transforming the prevention and treatment of cancer and infectious diseases.
Product pipeline
Inovio has a robust pipeline of product candidates targeting cancer and infectious diseases, with several programs entering late stages of development.
Inovio's technology is IMMUNO-INGENUITY in action
The ASPIRE™ activation immunotherapy platform is generating best-in-class immune responses in the fight against cancer and infectious diseases.